세계의 비침습적 산전 검사(NIPT) 시장 : 제품 및 서비스별, 수법별, 최종 사용자별 - 예측(-2029년)

The global non-invasive prenatal testing (NIPT) market is projected to reach USD 14.1 billion by 2029 from USD 7.2 billion in 2024 at a CAGR of 14.5%. The competitive landscape includes the analysis of the key growth strategies adopted by major players between January 2021 and June 2024. Players in the global non-invasive prenatal testing (NIPT) market have employed various strategies to expand their global footprint and increase their market shares such as partnerships, agreements, divestitures, expansions, and acquisitions.

"The Service segment accounted for the second-largest market share in the non-invasive prenatal testing (NIPT) market."

By products & service, service segment holds the second largest market share in the non-invasive prenatal testing (NIPT) market due to the growing preference for outsourcing complex diagnostic procedures to specialized service providers. These providers offer advanced technology and expertise, ensuring accurate and timely results, which are crucial for expectant parents making informed decisions about their pregnancies. Additionally, service providers often have the infrastructure to handle high volumes of tests, which can be more cost-effective for healthcare facilities than maintaining in-house capabilities. This outsourcing trend drives the substantial market share held by the service segment in the NIPT market.

"cfDNA in maternal plasma test segment of the non-invasive prenatal testing (NIPT) market is expected to witness the fastest CAGR."

By method type, the cfDNA in maternal plasma test segment has witnessed the fastest growth rate in the non-invasive prenatal testing (NIPT) market. This is largely due to its high accuracy and safety. Unlike traditional invasive methods such as amniocentesis, cfDNA testing involves a simple blood draw from the mother, minimizing risk to both the mother and the fetus. This non-invasive approach can detect a wide range of genetic conditions early in pregnancy with high sensitivity and specificity, leading to increased adoption by healthcare providers and expectant parents seeking reliable, low-risk prenatal screening options.

"The Microdeletion syndrome segment of the non-invasive prenatal testing (NIPT) market accounted for the second largest market share."

Based on application type, the microdeletion syndrome segment has accounted for the second largest market share in the Non-invasive Prenatal Testing (NIPT) market primarily due to the increasing awareness and advancements in genetic testing technologies. Microdeletion syndromes, which involve the deletion of small chromosome segments, can lead to significant developmental disorders and health issues in newborns. As a result, expectant parents are increasingly opting for NIPT to detect these conditions early, allowing for better preparedness and management. Moreover, NIPT offers a safe, non-invasive alternative to traditional diagnostic methods, further driving its adoption.

"Diagnostic laboratories segment of the non-invasive prenatal testing (NIPT) market holds the largest market share."

By end user type, the diagnostic laboratories segment has accounted for the largest market share, in the non-invasive prenatal testing (NIPT) market, due to their advanced technological capabilities and infrastructure, which enable accurate and efficient testing. These laboratories are equipped with cutting-edge equipment and specialized personnel, ensuring high-quality results. Additionally, they often have established relationships with healthcare providers and insurance companies, streamlining the process for patients and physicians. This integration of superior technology, expertise, and streamlined operations makes diagnostic laboratories the preferred choice for NIPT, thereby securing the largest market share in this segment.

"APAC region to have the third largest market share in the non-invasive prenatal testing (NIPT) market, by region."

In the APAC region, the non-invasive prenatal testing (NIPT) market has grown significantly. This is mainly because of the region's rapidly growing population and increasing awareness of prenatal health. With countries like China and India having large and expanding populations, there is a heightened demand for advanced prenatal testing solutions. The growing middle class in these countries is also becoming more health-conscious and willing to invest in high-quality healthcare services, including non-invasive prenatal testing. Additionally, the rising incidence of advanced maternal age and a greater emphasis on early disease detection further drive the demand for NIPT. These factors collectively contribute to APAC's leading position in the global market for non-invasive prenatal testing.

A breakdown of the primary participants (supply side) for the non-invasive prenatal testing (NIPT) market referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-25%, and Tier 3-40%
• By Designation: C-level-45%, Director Level-25%, and Others-30%
• By Region: North America-36%, Europe-26%, Asia Pacific-21%, Latin America-10%, and Middle East & Africa_ 7%

A breakdown of the primary participants (demand side) for the non-invasive prenatal testing (NIPT) market refer to for the report is provided below:

• By End User Type: Diagnostic Laboratory-65%, Hospitals-35%
• By Designation: Laboratories Technicians-55%, Doctor-45%
• By Region: North America-34%, Europe-27%, Asia Pacific-23%, Latin America-9%, and Middle East & Africa-7%

Key Market Players:

The prominent players in the non-invasive prenatal testing (NIPT) market include Illumina, Inc. (US), Natera, Inc. (US), Laboratory Corporation of America Holdings (US), Eurofins Sceintific (France), F. Hoffmann-La Roche AG (Switzerland). Revvity, Inc. (US), Thermo Fisher Scientific Inc (US), Agilent Technologies (US), GE Healthcare Technologies Inc. (US), Quest Diagnostics Incorporated (US), Sonic Healthcare Limited (Australia), Centogene N.V. (Germany), Qiagen N.V. (Germany), Pathwest Laboratory Medicine WA (Australia), Myriad Genetics Inc. (US), BGI Genomics Co., Ltd. (China), Oxford Nanopore Technologies Plc. (UK), Medgenome (India), Neuberg Diagnostics (India), Anngroad Gene Technology (China), Next Biosciences (South Africa), Lilac Insights (India), Invitae Corporation (US), Baylor Genetics (US), Raven (US).

Research Coverage:

The market analysis examines the non-invasive prenatal testing (NIPT) market in numerous segments. It seeks to estimate the market size and growth potential across many segments, including product and service, method type, application type, end user type and geography. The study also includes a detailed competitive analysis of the market's top competitors, as well as company profiles, significant insights about their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The study will assist industry leaders/new entrants in this market by providing information on the closest approximations of the non-invasive prenatal testing (NIPT) market and its segments. This research will assist stakeholders understand the competitive landscape, obtaining insights to better position their firms, and developing appropriate go-to-market strategies. The study will also assist stakeholders in understanding the market pulse and obtaining information on major market drivers, constraints, opportunities, and challenges.

This report provides insights into the following pointers:

• Analysis of key Drivers: Drivers (High risk of chromosomal abnormalities with increasing maternal age, Growing preference for non-invasive techniques over invasive methods, Improving reimbursement scenario for NIPT, Programs focusing on increasing awareness of NIPT), Restrains (High cost of procedures, Lack of insurance coverage), Opportunities (Untapped emerging markets, Technological Advancements), Challenges (Reliability of test results especially in obese women, Lack of skilled professionals) influencing the growth of the non-invasive prenatal testing (NIPT) market.
• Market Penetration: Comprehensive information on the product portfolios of the leading companies in the non-invasive prenatal testing (NIPT) market. The report breaks down the market by product and service type, method types, application types, end user types and region.
• Product Enhancement/Innovation: Detailed information about forthcoming trends and product launches in the non-invasive prenatal testing (NIPT) market.
• Market Development: Comprehensive data on attractive rising markets broken down by product and service type, method types, application types, end user types and region.
• Market Diversification: Comprehensive information on new products, expanding geographies, current advancements, and investments in the non-invasive prenatal testing (NIPT) market.
• Competitive Assessment: In-depth analysis of market share, growth strategies, product and service offerings, and capabilities of the main non-invasive prenatal testing (NIPT) products manufacturers.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 NON-INVASIVE PRENATAL TESTING MARKET OVERVIEW
• 4.2 EUROPE: NON-INVASIVE PRENATAL TESTING MARKET, BY APPLICATION
• 4.3 GEOGRAPHIC MIX: NON-INVASIVE PRENATAL TESTING MARKET, 2024-2029 (USD MILLION)
• 4.4 NON-INVASIVE PRENATAL TESTING MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS, 2024 VS. 2029

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 High risk of chromosomal abnormalities with increasing maternal age
    • 5.2.1.2 Growing preference for noninvasive techniques over invasive methods
    • 5.2.1.3 Improving reimbursement scenario
    • 5.2.1.4 Initiatives to spread awareness
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of procedures
    • 5.2.2.2 Lack of insurance coverage
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Untapped emerging markets
    • 5.2.3.2 Technological advancements
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Reliability of test results
    • 5.2.4.2 Lack of skilled professionals
• 5.3 INDUSTRY TRENDS
  • 5.3.1 DETECTION BEYOND TRISOMIES
  • 5.3.2 EARLIER GESTATIONAL AGE TESTING
  • 5.3.3 INTEGRATION WITH NGS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Cell-free DNA analysis
    • 5.4.1.2 NGS
    • 5.4.1.3 Digital PCR
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Microfluidics
    • 5.4.2.2 Nanotechnology
    • 5.4.2.3 Epigenetics analysis
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Ultrasound imaging
    • 5.4.3.2 Genome editing (CRISPR/Cas9)
    • 5.4.3.3 Liquid biopsy
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 SUPPLY CHAIN ANALYSIS
• 5.8 PORTER'S FIVE FORCE ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF SUPPLIERS
  • 5.8.4 BARGAINING POWER OF BUYERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.9.2 BUYING CRITERIA
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY ANALYSIS
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS
  • 5.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.12 TRADE ANALYSIS
  • 5.12.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
• 5.13 PRICING ANALYSIS
  • 5.13.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
  • 5.13.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.14 REIMBURSEMENT ANALYSIS
• 5.15 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.16 UNMET NEEDS/END-USER EXPECTATIONS
• 5.17 CASE STUDIES
  • 5.17.1 EVALUATION OF NIFTY TEST IN DETECTING FETAL CHROMOSOMAL ABNORMALITIES IN ASIAN POPULATIONS
  • 5.17.2 CLINICAL UTILITY OF HARMONY PRENATAL TEST IN A COHORT OF PREGNANT WOMEN
  • 5.17.3 ASSESSMENT OF PANORAMA TEST IN DETECTING FETAL GENETIC CONDITIONS
• 5.18 ADJACENT MARKET ANALYSIS
• 5.19 INVESTMENT & FUNDING SCENARIO
• 5.20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.21 IMPACT OF ARTIFICIAL INTELLIGENCE ON NON-INVASIVE PRENATAL TESTING MARKET

6 NON-INVASIVE PRENATAL TESTING MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 CONSUMABLES
    • 6.2.1.1 Assay kits & reagents
      • 6.2.1.1.1 Frequent use of reagents and assay kits to drive market
    • 6.2.1.2 Disposables
      • 6.2.1.2.1 Need for contamination-free workflow to boost demand for disposables
  • 6.2.2 INSTRUMENTS
    • 6.2.2.1 Ultrasound devices
      • 6.2.2.1.1 Popularity of ultrasound in fetal and embryonic imaging and safety to drive market
    • 6.2.2.2 NGS systems
      • 6.2.2.2.1 Rising use of NGS in NIPT to drive market
    • 6.2.2.3 PCR instruments
      • 6.2.2.3.1 Increasing research in prenatal genetic testing to boost market growth
    • 6.2.2.4 Microarrays
      • 6.2.2.4.1 Flexibility of chips and short processing times to support usage
    • 6.2.2.5 Other instruments
• 6.3 SERVICES
  • 6.3.1 NORTH AMERICA TO REGISTER HIGHEST DEMAND FOR TESTING SERVICES

7 NON-INVASIVE PRENATAL TESTING MARKET, BY METHOD

• 7.1 INTRODUCTION
• 7.2 ULTRASOUND DETECTION
  • 7.2.1 ULTRASOUND DETECTION TO DOMINATE NIPT MARKET
• 7.3 BIOCHEMICAL SCREENING TESTS
  • 7.3.1 HIGH INCIDENCE OF GENETIC DISORDERS AND INCREASING FOCUS ON PRENATAL TESTING TO SUPPORT MARKET GROWTH
• 7.4 CFDNA IN MATERNAL PLASMA TESTS
  • 7.4.1 CFDNA IN MATERNAL PLASMA TESTS SEGMENT TO REGISTER HIGHEST CAGR

8 NON-INVASIVE PRENATAL TESTING MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 TRISOMY
  • 8.2.1 TRISOMY TO HOLD LARGEST SHARE OF APPLICATIONS MARKET AND SHOW HIGHEST GROWTH
• 8.3 MICRODELETION SYNDROME
  • 8.3.1 INCREASING AWARENESS TO SUPPORT DEMAND FOR TESTING
• 8.4 OTHER APPLICATIONS

9 NON-INVASIVE PRENATAL TESTING MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 DIAGNOSTIC LABORATORIES
  • 9.2.1 RISING RESEARCH INTENSITY TO DRIVE USAGE OF NIPT PRODUCTS IN DIAGNOSTIC LABS
• 9.3 HOSPITALS
  • 9.3.1 RISING INCIDENCE OF GENETIC DISORDERS AND INCREASING FOCUS ON PRENATAL TESTING TO PROPEL MARKET

10 NON-INVASIVE PRENATAL TESTING MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 10.2.2 US
    • 10.2.2.1 High incidence of chromosomal syndromes to drive demand
  • 10.2.3 CANADA
    • 10.2.3.1 Unfavorable reimbursement scenario for NIPT to challenge market growth
• 10.3 EUROPE
  • 10.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 10.3.2 UK
    • 10.3.2.1 High incidence of genetic abnormalities to increase demand for prenatal testing
  • 10.3.3 GERMANY
    • 10.3.3.1 Strong R&D and increasing healthcare spending to drive market
  • 10.3.4 FRANCE
    • 10.3.4.1 Favorable insurance coverage for prenatal testing to increase adoption of NIPT
  • 10.3.5 ITALY
    • 10.3.5.1 Favorable funding scenario for genomics to drive market
  • 10.3.6 SPAIN
    • 10.3.6.1 Rising funding and expanding research infrastructure to propel market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 10.4.2 JAPAN
    • 10.4.2.1 Rising maternal age to propel incidence of chromosomal disorders
  • 10.4.3 CHINA
    • 10.4.3.1 China to register highest growth in Asia Pacific market
  • 10.4.4 INDIA
    • 10.4.4.1 Rising disposable income and demand for better health to support market growth
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Strong research ecosystem for NIPT to drive market
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Increasing scope for genomic research to support market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 10.5.2 BRAZIL
    • 10.5.2.1 Rising focus on clinical genomics to drive demand for NIPT
  • 10.5.3 MEXICO
    • 10.5.3.1 High incidence of Down syndrome to propel demand
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Launch of genomic initiatives to drive market
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN NON-INVASIVE PRENATAL TESTING MARKET
• 11.3 REVENUE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 R&D EXPENDITURE OF KEY PLAYERS
• 11.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.6.1 STARS
  • 11.6.2 EMERGING LEADERS
  • 11.6.3 PERVASIVE PLAYERS
  • 11.6.4 PARTICIPANTS
  • 11.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.6.5.1 Company footprint
    • 11.6.5.2 Product & service footprint
    • 11.6.5.3 Method footprint
    • 11.6.5.4 Application footprint
    • 11.6.5.5 End-user footprint
    • 11.6.5.6 Region footprint
• 11.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.7.1 PROGRESSIVE COMPANIES
  • 11.7.2 DYNAMIC COMPANIES
  • 11.7.3 STARTING BLOCKS
  • 11.7.4 RESPONSIVE COMPANIES
  • 11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.8 VALUATION & FINANCIAL METRICS
• 11.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 11.10 COMPETITIVE SCENARIO
  • 11.10.1 PRODUCT & SERVICE LAUNCHES
  • 11.10.2 DEALS
  • 11.10.3 EXPANSIONS
  • 11.10.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 ILLUMINA, INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products & services offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches & approvals
      • 12.1.1.3.2 Expansions
      • 12.1.1.3.3 Other developments
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 NATERA, INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products & services offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product & service launches and approvals
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products & services offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 EUROFINS SCIENTIFIC
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products & services offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Service launches
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 F. HOFFMANN-LA ROCHE AG
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products & services offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 REVVITY, INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products & services offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches
      • 12.1.6.3.2 Deals
  • 12.1.7 THERMO FISHER SCIENTIFIC INC.
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products & services offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 AGILENT TECHNOLOGIES
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products & services offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
  • 12.1.9 GE HEALTHCARE TECHNOLOGIES INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products & services offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product & service launches and approvals
      • 12.1.9.3.2 Expansions
  • 12.1.10 QUEST DIAGNOSTICS INCORPORATED
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products & services offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches
      • 12.1.10.3.2 Deals
  • 12.1.11 SONIC HEALTHCARE LIMITED
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products & services offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
      • 12.1.11.3.2 Expansions
  • 12.1.12 CENTOGENE N.V.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products & services offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product launches
      • 12.1.12.3.2 Deals
      • 12.1.12.3.3 Other developments
  • 12.1.13 QIAGEN N.V.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products & services offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches
      • 12.1.13.3.2 Deals
      • 12.1.13.3.3 Expansions
  • 12.1.14 PATHWEST LABORATORY MEDICINE WA
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products & services offered
  • 12.1.15 MYRIAD GENETICS, INC.
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products & services offered
• 12.2 OTHER PLAYERS
  • 12.2.1 BGI GENOMICS CO., LTD.
  • 12.2.2 OXFORD NANOPORE TECHNOLOGIES PLC
  • 12.2.3 MEDGENOME
  • 12.2.4 NEUBERG DIAGNOSTICS
  • 12.2.5 ANNOROAD GENE TECHNOLOGY
  • 12.2.6 NEXT BIOSCIENCES
  • 12.2.7 LILAC INSIGHTS
  • 12.2.8 INVITAE CORPORATION
  • 12.2.9 BAYLOR GENETICS
  • 12.2.10 RAVGEN

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS